The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. 1990

E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
Division of Infectious Disease, University of California, Davis Medical Center, Sacramento 95817.

The concomitant administration of acetaminophen to HIV-positive patients receiving zidovudine (AZT) therapy has previously been thought to increase the likelihood of the toxicity of AZT due to increased serum levels, resulting from hypothesized metabolic competition. We measured serum AZT and metabolite levels by HPLC in HIV-infected patients taking regular doses of AZT with and without acetaminophen administration. In all patients, serum levels of AZT and the glucuronidated metabolite (GAZT) were similar with and without acetaminophen administration. AZT serum levels were not increased (p less than 0.05). We believe that the rationale for withholding acetaminophen from patients receiving AZT should be re-evaluated.

UI MeSH Term Description Entries
D008297 Male Males
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000082 Acetaminophen Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. Acetamidophenol,Hydroxyacetanilide,Paracetamol,APAP,Acamol,Acephen,Acetaco,Acetominophen,Algotropyl,Anacin-3,Datril,N-(4-Hydroxyphenyl)acetanilide,N-Acetyl-p-aminophenol,Panadol,Tylenol,p-Acetamidophenol,p-Hydroxyacetanilide,Anacin 3,Anacin3
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
June 1992, British journal of clinical pharmacology,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
January 1990, Journal of acquired immune deficiency syndromes,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
March 1993, The American journal of psychiatry,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
May 1990, American family physician,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
March 1997, Methods and findings in experimental and clinical pharmacology,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
January 1998, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
October 1989, American family physician,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
February 2001, Journal of clinical pharmacology,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
October 2003, HIV medicine,
E M Steffe, and J H King, and J F Inciardi, and N F Flynn, and E Goldstein, and T S Tonjes, and L Z Benet
August 1994, AIDS (London, England),
Copied contents to your clipboard!